Deloitte’s report, titled “Role of Royalties in Funding Biopharma Innovation,” is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma royalties.
We are the world’s largest buyer of biopharmaceutical royalties and a leading funder of innovation in life sciences.
Learn moreWe are the leading partner funding innovation in life sciences with more than 60% global market share. Our unique capabilities to provide tailored funding solutions and customize win-win partnerships have positioned us as the partner of choice in the biopharma ecosystem.
We create value for our stakeholders by funding innovation across the life sciences ecosystem. Our policies and practices are designed to minimize our sustainability-related risk and uphold our commitments to our stakeholders and partners.
Held in partnership with the University of Cambridge and the Massachusetts Institute of Technology since 2019, the Accelerating Bio-Innovation Conference is an interdisciplinary summit that brings to light the triumphs and hurdles in drug discovery and development. The event brings together thought leaders from the bio-innovation sphere to engage in crucial debates and discussions confronting pioneers in the world of new biopharmaceuticals, bridging the realms of science, investing and innovative therapeutics.
Find out more
